Our Facilities

Ligand lifts ’13 outlook; signs a license deal

Ligand Pharmaceuticals Inc. signed a global licensing and supply deal with Spectrum Pharmaceuticals Inc. to develop Ligand’s Captisol-enabled melphalan for use as part of multiple myeloma transplant programs, a deal potentially valued at more than $53 million. Ligand also raised its guidance for the year as it projected better-than-expected first-quarter results. Under the deal, Ligand will…
Read the full article…

KU spinout HylaPharm begins producing cancer drug delivery technology

A University of Kansas startup company has begun producing a new drug delivery technology that could make cancer treatments safer and more effective. HylaPharm, a drug delivery company founded in 2010 by a team of KU faculty, is now producing its patented HylaPlat technology, which delivers chemotherapy drugs directly to cancer cells in tumors and…
Read the full article…

UMKC Entrepreneurship Scholars Program Taking Applications Now

UMKC’s Institute for Entrepreneurship and Innovation is currently accepting applications to its highly-acclaimed Entrepreneurship Scholars Program.  The E-Scholars program, open to the general public, is a 12-month certificate program designed to provide promising entrepreneurs with the skills and knowledge needed to launch world-class ventures. The E-Scholars Program is open to anyone who has an idea…
Read the full article…

Website designed & developed by New Media Samurai (NMS3)